Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Influence of growth hormone receptor (GHR) exon 3 and-202A/C IGFBP-3 genetic polymorphisms on clinical and biochemical features and therapeutic outcome of patients with acromegaly

Full text
Jallad, Raquel S. [1] ; Trarbach, Ericka B. [2] ; Duarte, Felipe H. [1] ; Jorge, Alexander A. L. [2] ; Bronstein, Marcello D. [1]
Total Authors: 5
[1] Univ Sao Paulo, Sch Med, Hosp Clin, Neuroendocrine Unit, BR-05403010 Sao Paulo, SP - Brazil
[2] Univ Sao Paulo, Sch Med, Lab Cellular & Mol Endocrinol LIM25, BR-01246903 Sao Paulo - Brazil
Total Affiliations: 2
Document type: Journal article
Source: Pituitary; v. 18, n. 5, p. 666-673, OCT 2015.
Web of Science Citations: 8

The association of GHR-exon 3 and -202 A/C IGFBP3 polymorphisms with clinical presentation, biochemical measurements and response to therapies in acromegaly have been suggested. To evaluate the presence of these polymorphisms in acromegaly and their influence on clinical and laboratorial characteristics of patients at diagnosis and after treatment in a large cohort of acromegalic patients. This is a cross-sectional study developed in a single tertiary reference center. Clinical data were obtained from the medical records of 186 acromegalic patients (116 women, age range 21-88 years). GH and IGF1 levels and GHR-exon 3 and -202 A/C IGFBP3 polymorphisms were evaluated in the same hospital. At diagnosis, serum GH concentrations were lower in patients with GHR-d3 genotype than those with GHR-fl, whereas an association of lower IGFBP3 levels with d3 allele was observed only after neurosurgical or medical treatments. However, these associations were not confirmed in posterior statistical analysis. Our results suggest that GHR-exon 3 and -202 A/C IGFBP3 polymorphisms did not show any consistent association on clinical and laboratorial features of acromegalic patients even after treatment. (AU)

FAPESP's process: 10/11718-1 - Polymorphisms in genes of GH receptor (GHR) and IGFBP3 in acromegaly: correlation with clinical / laboratory parameters and response to therapy
Grantee:Marcello Delano Bronstein
Support type: Regular Research Grants